Tag: Telmisartan
-
Fatty Liver Cure: Could Pemafibrate and Telmisartan Reversethe Disease?
New Study Suggests a Surprising Duo for Fatty Liver Cure Fatty liver disease, or MASLD/NAFLD as it’s increasingly called, has earned its reputation as a global silent killer. The condition unfolds quietly as excess fat accumulates in liver cells, potentially progressing to inflammation, fibrosis, and even cirrhosis or liver cancer. While lifestyle changes remain the…
-
Fatty Liver Cure: Pemafibrate and Telmisartan Combo May Reverse MASLD
New hope in fatty liver disease: a drug combination that could reverse MASLD Fatty liver disease, now increasingly called MASLD (Metabolic Associated Steatosis with Liver Disease), affects millions worldwide and is rising in prevalence alongside obesity and sedentary lifestyles. While lifestyle changes remain essential, researchers have long searched for therapies that can halt or reverse…
-
Fatty Liver Cure: How Two Common Cardiovascular Drugs Could Reverses Fatty Liver Disease
The Breakthrough: A New Hope for Fatty Liver Disease Fatty liver disease, or MASLD (formerly NAFLD), affects millions worldwide and has long lacked a proven medical cure. A recent study from researchers at the University of Barcelona suggests a provocative approach: combining two widely used cardiovascular drugs—pemafibrate and telmisartan—to actively reduce liver fat and improve…
-
Repurposed antihypertensive and lipid-lowering drugs show promise against MASLD
New hope for MASLD through drug repurposing Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the world’s most common liver disorder, affecting roughly one in three adults. It involves fat buildup in liver cells and is linked to serious liver outcomes and a heightened risk of cardiovascular mortality. A recent study from the University of…
-
Repurposed Antihypertensive and Lipid-Lowering Drugs Show Promise Against MASLD
MASLD: A Global Liver Disease in Need of Safe, Effective Treatments Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as the world’s most common liver disorder, affecting roughly one in three adults. The disease is characterized by fat buildup in liver cells, which can progress to liver dysfunction and is closely linked to higher…